By Katherine Hamilton
Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq.
The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year.
The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday.
Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said.
The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
April 01, 2025 15:15 ET (19:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。